Head-to-head · The Match Score
Eden vs Next Vial
Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 58 edge.
Eden
#7 · Grade B+
People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.
Visit EdenNext Vial
#333 · Grade C
People seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.
Visit Next VialFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | Eden | Next Vial |
|---|---|---|
| Semaglutide | $239/mo | $250/mo (compounded) |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | All 50 states | 49 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injectable only | Injectable only |
| Match Score | 87 · B+ | 58 · C |
Eden edges out Next Vial, 87 to 58 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.
Next Vial is still a fair pick if its strengths line up with yours — best for: People seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.
Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
- Eden vs CoreAge Rx
- Eden vs Strut Health
- Eden vs HealthRX
- Eden vs ShedRx
- Eden vs Ondra Health
- Eden vs Enhance MD
Or browse alternatives to Eden and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.